Ibrutinib for the treatment of mantle cell lymphoma

References

• Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012;122(10):3416-23
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang H, Fang W. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113(4):791-8
   PubMed Web of Science ®Google Scholar
• McKay P, Leach M, Jackson R, et al. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol 2012;159(4):405-26
   PubMed Web of Science ®Google Scholar
• Eve H, Furtado M, Hamon M, Rule S. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009;27(32):189-90
   PubMed Web of Science ®Google Scholar
• Hsi ED, Martin P. Indolent mantle cell lymphoma. Leuk Lymphoma 2013;55(4):761-7
   PubMedGoogle Scholar
• Martin P, Chadburn A, Christos P. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27(8):1209-13
   PubMed Web of Science ®Google Scholar
• Vose JM. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2013;88(12):1082-8
   PubMedGoogle Scholar
• Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012;156(3):346-53
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012;158(3):355-62
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72(20):5307-16
   PubMed Web of Science ®Google Scholar
• Rickert R. New insights into pre-BCR and BCR signalling with relevance to C cell malignancies. Nature 2013;13(8):578-91
   Web of Science ®Google Scholar
• Brett LK, Williams ME. Current and emerging therapies in mantle cell lymphoma. Curr Treat Options Oncol 2013;14(2):198-211
   PubMed Web of Science ®Google Scholar
• Mohamed A, Yu L, Backesjo C, et al. Bruton’s tyrosine kinase (Btk) : function, regulation, and transformation with special emphasis on the PH domain. 2009;228(1):58-73
   Google Scholar
• Buggy JJ. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012;32(2):119-32
   Google Scholar
• Satterthwaite AB, Witte ON. The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. 2000;175:120-7
   Google Scholar
• Bruton O. Agammaglobulinemia. Pediatrics 1998;102(1 Pt 2):213-15
   PubMedGoogle Scholar
• Ponader S. Burger J a. Bruton’s Tyrosine Kinase: from X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies. J Clin Oncol 2014;32(17):1830-9
   PubMed Web of Science ®Google Scholar
• Choi M, Kipps T. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J 2013;18(5):404-10
   Web of Science ®Google Scholar
• Burger JA, Buggy JJ. Emerging drug profiles; Bruton’s Tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 2013;54(11):2385-91
   PubMed Web of Science ®Google Scholar
• Baba Y, Hashimoto S, Matsushita M, et al. BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci USA 2001;98(5):2582-6
   PubMed Web of Science ®Google Scholar
• Psyrri A, Papageorgiou S, Liakata E, et al. Phosphatidylinositol 3’-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009;15(18):5724-32
   PubMed Web of Science ®Google Scholar
• Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013;31(1):128-30
   PubMed Web of Science ®Google Scholar
• Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013;23(6):410-21
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1):88-94
   PubMed Web of Science ®Google Scholar
• Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res 2013;37(10):1271-7
   PubMed Web of Science ®Google Scholar
• Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA 2013;110(45):18250-5
   PubMed Web of Science ®Google Scholar
• Pighi C, Gu T-L, Dalai I, et al. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr) 2011;34(2):141-53
   PubMedGoogle Scholar
• Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011;118(11):3088-95
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006;132(3):303-16
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107(29):13075-80
   PubMed Web of Science ®Google Scholar
• Bhatt V, Alejandro L, Michael A, Ganetsky A. The promising impact of ibrutinib, a Bruton’s tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy 2013;34(3):303-14
   PubMedGoogle Scholar
• Maddocks K, Blum KA. Ibrutinib in B-cell Lymphomas. Curr Treat Options Oncol 2014;15(2):226-37
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2013;369(6):507-16
   PubMed Web of Science ®Google Scholar
• Farooqui M, Lozier J, Valdez J, et al. Ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation. Blood 2012;120:abstract 1789
   Google Scholar
• Chang BY, Francesco M, De Rooij MFM, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013;122(14):2412-24
   PubMed Web of Science ®Google Scholar
• Cameron F, Sanford M. Ibrutinib: first global approval. Drugs 2014;74(2):263-71
   PubMed Web of Science ®Google Scholar
• Blum KA, Christian B, Flynn J, et al. A phase I trial of the Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed/refractory non-Hodgkin’s. Am Soc Hematol 2012;21(3):1643
   Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study of the Bruton’s tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantle cell lymphoma. Available from: http://www.clinicaltrials.gov/show/NCT01776840
   Google Scholar
• Flinn IW, Berdeja J, Freidbery J, et al. Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-Cell Non-Hodgkin’s lymphoma (NHL). Blood 2013;122(21):852
   Google Scholar
• ClinicalTrials.gov. A study combining ibrutinib. with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. Available from: http://clinicaltrials.gov/show/NCT01569750
   Google Scholar
• Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013;6(1):59
   PubMedGoogle Scholar
• Aalipour A, Advani RH. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br J Haematol 2013;163(4):436-43
   PubMed Web of Science ®Google Scholar
• Middendorp S, Dingjan GM, Maas A, et al. Function of Bruton’s tyrosine kinase during B cell development is partially independent of its catalytic activity. J Immunol 2003;171:5988-96
   PubMed Web of Science ®Google Scholar
• Yasuhiro T, Yoshizawa T, Daub H, et al. ONO-WG- 307, a novel, potent and selective inhibitor of Bruton’s tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways. Cancer Res 2012;72:abstract 2021
   Google Scholar
• Kozaki R, Yoshizawa T, Yasuhiro T, et al. Development of a Bruton’s tyrosine kinase (Btk) inhibitor - ONO-WG-307, a potential treatment for B-cell malignancies. AACR 2012;857:abstract 857
   Google Scholar
• Rule S, Shah N, Salles G, et al. A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory B-cell lymphoma. Blood 2013;122(21):abstract 4397
   Google Scholar
• Salles G, Karlin L, Rule S, et al. A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory and high risk chronic lymphocytic leukaemia (CLL). Blood 2013;122(21):abstract 676
   Google Scholar
• Evans E, Tester R, Aslanian S, et al. Clinical development of AVL-292; a potent, selective covalent Btk inhibitor for the treatment of B cell malignancies. Blood 2011;118(21):3485
   Google Scholar
• Brown J, Harb W, Hill H, et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton’s tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). Blood 2013;122(21):abstract 1630
   Google Scholar
• ClinicalTrials.gov. A phase IB study Of The BTKi CC-292 combined with lenalidomide in adults patients with relapsed/refractory B-Cell lymphoma (CLEAR). Available from: http://clinicaltrials.gov/show/NCT01766583
   Google Scholar
• Uckun F, Zheng Y, Cetkovic-Cvrlje M, et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-betamethyl- N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton’s tyrosine kinase. Clin Cancer Res 2002;8(5):1224-33
   PubMed Web of Science ®Google Scholar
• Uckun F, Dibirdik I, Qazi S, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bio Org Med Chem 2007;15(2):800-14
   PubMedGoogle Scholar
• Mahajan S, Ghosh S, Sudbeck E, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-betamethyl- N-(2, 5-dibromophenyl)propenamide]. J Biol Chem 1999;274(14):9587-99
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. Safety, PK/PD, food effect study of orally administered HM71224 in healthy adult male volunteers. Available from: http://clinicaltrials.gov/show/NCT01765478
   Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27(23):3822-9
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013;31(29):3688-95
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study of ibrutinib (a Bruton’s tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who have received at least one prior therapy. Available from: http://clinicaltrials.gov/show/NCT01646021
   Google Scholar
• O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15(1):48-58
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT). Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net) Blood 2012;120(21):abstract 151
   Google Scholar
• Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European. Blood 2005;105(7):2677-84
   PubMed Web of Science ®Google Scholar
• Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117(1):26-38
   PubMed Web of Science ®Google Scholar
• Zucca E, Bertoni F. Toward new treatments for mantle-cell lymphoma? N Engl J Med 2013;369(6):571-2
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Rituxan/bendamustine/PCI-32765 in relapsed DLBCL, MCL, or indolent non-Hodgkin’s lymphoma. Available from: http://clinicaltrials.gov/show/NCT01479842
   Google Scholar
• ClinicalTrials.gov. A long-term extension study of PCI-32765 (ibrutinib). Available from: http://clinicaltrials.gov/show/NCT01804686
   Google Scholar
• ClinicalTrials.gov. Phase 2 ibrutinib + rituximab in relapsed/refractory mantle cell lymphoma (R/R MCL). Available from: http://clinicaltrials.gov/show/NCT01880567
   Google Scholar
• ClinicalTrials.gov. Ublituximab + ibrutinib in select B-cell malignancies. Available from: http://clinicaltrials.gov/show/NCT02013128
   Google Scholar
• ClinicalTrials.gov. Lenalidomide and ibrutinib in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Available from: http://clinicaltrials.gov/show/NCT01955499
   Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20(3):520-5
   PubMed Web of Science ®Google Scholar
• Kouroukis C, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle‐cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21(9):1740-5
   PubMed Web of Science ®Google Scholar
• Renner C, Zinzani PL, Gressin R, et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012;97(7):1085-91
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25(2):341-7
   PubMed Web of Science ®Google Scholar
• Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012;159(2):154-63
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SFH, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005;23(4):705-11
   PubMed Web of Science ®Google Scholar